Lab
Proteus Molecular and Clinical Lab LLC
Proteus Molecular and Clinical Lab LLC was paid $3.21M by Medicaid between Jan 2018 and Dec 2024, across 46 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 47% of everything it billed.
33Billing provider infoPROTEUS MOLECULAR AND CLINICAL LAB LLC
HOMEWOOD, AL 35209
HOMEWOOD, AL 35209
33aNPI1538542196assigned 07/01/2015
33bProvider typeClinical Medical Laboratory
28Total paid$3.21M
24GClaims80,970
24DCodes billed46
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#16 of 61
Median peer was paid$46K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 410 | $12K | |
| 2019 | 2,413 | $130K | |
| 2020 | 9,149 | $408K | |
| 2021 | 18,665 | $726K | |
| 2022 | 26,003 | $945K | |
| 2023 | 16,830 | $673K | |
| 2024incomplete | 7,500 | $314K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 47% | 10,245 | 8,604 | $1.50M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 14% | 8,666 | 5,706 | $462K |
| 87481 | 12% | 7,174 | 6,124 | $398K | |
| 87640 | 3.6% | 9,293 | 7,950 | $116K | |
| 87500 | 2.9% | 7,082 | 6,056 | $92K | |
| 87653 | 2.8% | 7,096 | 6,065 | $91K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.8% | 5,335 | 3,756 | $90K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.1% | 2,193 | 1,960 | $66K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.7% | 577 | 503 | $55K |
| 87634 | 1.5% | 2,078 | 1,872 | $48K | |
| 87641 | 1.4% | 4,068 | 3,489 | $46K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.3% | 2,392 | 2,108 | $43K |
34 more codes
| 87486 | 1.1% | 2,706 | $37K | |
| 87581 | 1.1% | 2,702 | $36K | |
| 87541 | 1.1% | 2,577 | $35K | |
| 87498 | <1% | 2,193 | $28K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 597 | $16K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 284 | $14K |
| 87631 | <1% | 284 | $13K | |
| 81230 | <1% | 65 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 245 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 248 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 245 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 14 | $2K |
| 81225 | <1% | 22 | $1K | |
| 87186 | <1% | 17 | $971.12 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 101 | $956.99 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 54 | $836.59 |
| 80053 | Comprehensive metabolic panel | <1% | 65 | $729.50 |
| 81003 | <1% | 327 | $435.88 | |
| 81226 | <1% | 25 | $356.50 | |
| 81328 | <1% | 58 | $233.74 | |
| 87070 | <1% | 13 | $231.38 | |
| 87077 | <1% | 17 | $191.04 | |
| 80061 | Lipid panel | <1% | 13 | $182.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16 | $63.60 |
| 0002A | <1% | 53 | $56.78 | |
| 81291 | <1% | 22 | $52.40 | |
| 0001A | <1% | 51 | $16.94 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 993 | $2.51 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 29 | $0.00 |
| 81241 | 0% | 21 | $0.00 | |
| 81401 | 0% | 31 | $0.00 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 599 | $0.00 |
| 81231 | 0% | 63 | $0.00 | |
| 81240 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIFFITH, MICHAEL (MEMBER MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Michael D. Griffith, PH.D. & Assoc., LLC | Lima, OH | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.